Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 6 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 2 |
| Biomarkers in Drug Discovery Introduction | 10 | 2 |
| Introduction | 10 | 1 |
| GBI Research Report Guidance | 11 | 1 |
| Biomarkers in Drug Discovery Overview | 12 | 23 |
| History of Biomarkers | 12 | 2 |
| Biomarker Classification | 14 | 1 |
| Biomarker Categories | 15 | 1 |
| Types of Biomarkers | 16 | 1 |
| Type 0 Markers | 16 | 1 |
| Type I Marker | 16 | 1 |
| Type II Biomarker | 16 | 1 |
| Example of Type 0, I and II Biomarker | 17 | 1 |
| Reasons Surrogate Endpoints Fail | 17 | 2 |
| Biomarker Discovery and the Validation Process | 19 | 1 |
| Product Development Process from Discovery to Launch | 20 | 1 |
| Discovery | 20 | 1 |
| Development | 20 | 1 |
| Launch | 20 | 1 |
| General Application of Biomarkers | 21 | 1 |
| Biomarkers in Drug Discovery and Drug Development | 22 | 1 |
| Role of Biomarkers in the Drug Discovery Process | 23 | 1 |
| Application of Biomarkers in Disease Diagnosis and Prognosis | 23 | 2 |
| Potential Impact of Biomarkers on Disease States | 25 | 1 |
| Population Genetics Study | 26 | 1 |
| Environmental Health and Risk Assessment | 27 | 1 |
| Role of Biomarkers in Environmental Health and Risk Assessment | 28 | 1 |
| Health Risk Assessment | 28 | 1 |
| Clinical Diagnosis of Environmental Poisoning | 28 | 1 |
| Biological Screening and Monitoring | 28 | 1 |
| Toxicology Studies in Dietary Items or Nutraceuticals | 28 | 1 |
| Application of Biomarkers in Drug Discovery | 29 | 1 |
| Lead Identification and Optimization | 29 | 1 |
| Potential Role of Biomarkers in Lead Identification and Optimization | 30 | 1 |
| Target Validation | 30 | 1 |
| Toxicological Assay (Preclinical and Clinical) | 30 | 1 |
| Mechanism of Action | 31 | 1 |
| Monitor Therapy and Dose Response | 31 | 1 |
| Stratify Patient Population | 31 | 1 |
| Filing and Post Marketing Surveillance | 32 | 1 |
| Benefits of Biomarker Utilization | 32 | 1 |
| Disease Understanding | 32 | 1 |
| Project Prioritization through Early Attrition | 32 | 1 |
| Streamlining Clinical Trials | 32 | 1 |
| Reducing Cost of Drug Development | 33 | 1 |
| Speeding Drug Development | 33 | 1 |
| Avoiding Adverse Drug Reactions (ADR) and Rationalizing Dosing Regimen | 33 | 1 |
| Drug Repositioning | 33 | 1 |
| Challenges in Biomarker Utilization | 34 | 1 |
| Variability | 34 | 1 |
| Validity | 34 | 1 |
| Measurement Errors | 34 | 1 |
| Bias | 34 | 1 |
| Confounding | 34 | 1 |
| Cost | 34 | 1 |
| Acceptability | 34 | 1 |
| Biomarkers in Drug Discovery Case Study | 35 | 2 |
| Cell Signaling Technology Enters Into Co-Marketing Agreement with Astellas Pharma | 35 | 1 |
| Definition | 35 | 1 |
| About Lung Cancer | 35 | 1 |
| Company Profile | 35 | 1 |
| Technology Used | 36 | 1 |
| Market Information | 36 | 1 |
| Advantages | 36 | 1 |
| Future Prospect | 36 | 1 |
| Biomarkers in Drug Discovery Market Characterization | 37 | 13 |
| Market Overview | 37 | 1 |
| Market Size and Forecasts | 37 | 1 |
| Global Biomarkers Market Size | 37 | 1 |
| Global Biomarkers Market Segmentation by Therapy Area | 38 | 1 |
| Global Biomarkers Drug Discovery Market | 39 | 1 |
| Global Biomarker s Molecular Diagnostics Market | 40 | 1 |
| Global Biomarkers Others Market | 41 | 1 |
| Global Biomarkers Market Segmentation | 42 | 1 |
| Drivers and Restraints | 43 | 1 |
| Drivers for the Global Biomarkers Market | 43 | 1 |
| Time Saving and Inexpensive - Biomarkers Cut Down Drug Discovery Cost By $100m and three-four Years for Each Drug | 43 | 1 |
| Better Regulatory Norms and Validation Procedures Encourage Growth of the Biomarker s Market | 44 | 1 |
| Broad Applications Extensive Range of Applications in Different Industrial Sectors Drives the Biomarkers Market towards Extensive Growth | 44 | 1 |
| Integration of Omics Increases the Scope of Application for Biomarkers in Other Technologies Leading to Growth | 44 | 1 |
| Advantageous Over Conventional Drug Discovery Methods Non-Invasive, Sensitive and Selective | 45 | 1 |
| Barriers for the Global Biomarkers Market | 46 | 1 |
| Awareness Gap Lack of Awareness about Intelligent and Novel Technological Advances Such as Biomarker Assays Restrain Market Growth | 46 | 1 |
| Diagnostic Uncertainty Complex Biomarker Based Techniques May Lead to False Positive Results Misleading the Clinical Trails | 46 | 1 |
| Funding Funding Organizations Require Strong Clinical Data and Validation to Provide Funds for the Research and Testing Phases of Biomarkers, Restraining Market Growth | 46 | 1 |
| Cumbersome and Lengthy Development Procedure Discourages Biomarker Research by the Pharmaceutical Sector | 46 | 1 |
| Unmet Needs Biomarkers Fulfilling the Unmet Needs of Drug Discovery | 47 | 1 |
| High Attrition Rates | 48 | 1 |
| High Drug Discovery Cost | 48 | 1 |
| Time Consuming | 49 | 1 |
| Safety and Efficacy | 49 | 1 |
| Invasiveness, Selectivity and Sensitivity | 49 | 1 |
| Biomarkers in Drug Discovery Trends Analysis | 50 | 6 |
| Regulatory Landscape (Current and Future) | 50 | 1 |
| Investigative/Exploratory Biomarker | 50 | 1 |
| Probable Valid Biomarker | 50 | 1 |
| Known Valid Biomarker | 50 | 1 |
| Regulatory Biomarker | 50 | 1 |
| Letter Of Intent to Propose Biomarker Qualification | 50 | 1 |
| Administrative Structure | 50 | 1 |
| Biomarker Qualification Overview | 50 | 1 |
| Overall Summaries of the Following (as appropriate): | 51 | 1 |
| Questions for FDA | 51 | 1 |
| Structure of Biomarker Qualification Briefing Document | 51 | 2 |
| Validated Biomarker | 53 | 2 |
| Regulatory Acceptance of Valid Biomarkers | 55 | 1 |
| Regulatory Guidance from the FDA, EMEA, and MHLW (Japan) | 55 | 1 |
| Biomarkers in Drug Discovery Technology Adoptions | 56 | 3 |
| Unmet Need - Drug Discovery | 57 | 1 |
| Biomarkers Technology Exists to Fulfill Unmet Drug Discovery Needs | 57 | 1 |
| Increased Awareness among Pharmaceutical and Research Sector | 57 | 1 |
| Increasing Adoption Due to Wide Application | 57 | 1 |
| Biomarkers Future Drug Discovery Unmet Needs Fulfilled | 57 | 2 |
| Biomarkers in Drug Discovery Competitive Landscape | 59 | 23 |
| Key Biomarkers Players | 59 | 1 |
| Quest Diagnostics | 60 | 1 |
| SWOT Analysis | 61 | 1 |
| Life Technologies Corporation | 62 | 1 |
| SWOT Analysis | 63 | 1 |
| Vermillion | 64 | 1 |
| SWOT Analysis | 65 | 1 |
| BG Medicine | 66 | 1 |
| SWOT Analysis | 67 | 1 |
| Menarini | 68 | 1 |
| SWOT Analysis | 69 | 1 |
| Abbott | 70 | 1 |
| SWOT Analysis | 71 | 1 |
| Roche | 72 | 1 |
| SWOT Analysis | 73 | 1 |
| Genentech | 74 | 1 |
| SWOT Analysis | 75 | 1 |
| Affymetrix | 76 | 1 |
| SWOT Analysis | 77 | 1 |
| Amgen | 78 | 1 |
| SWOT Analysis | 79 | 1 |
| Global Biomarkers Market Geographic Landscape | 80 | 2 |
| Biomarkers in Drug Discovery Pipeline Analysis | 82 | 6 |
| Pipeline Analysis | 82 | 1 |
| Biomarkers in Discovery Phase | 82 | 1 |
| Biomarkers in Phase I | 83 | 1 |
| Biomarkers in Phase II | 84 | 1 |
| Biomarkers in Phase III | 84 | 1 |
| Biomarkers in Phase IV | 84 | 1 |
| Pipeline Analysis by Phase | 85 | 1 |
| Pipeline Analysis Therapeutic Class | 86 | 1 |
| Pipeline Analysis by Geography | 87 | 1 |
| Biomarkers in Drug Discovery Strategic Consolidations | 88 | 12 |
| Strategic Consolidations by Deal Type | 88 | 1 |
| Mergers and Acquisitions | 89 | 2 |
| Mergers and Acquisitions by Geography | 91 | 1 |
| Major M&A Deals | 91 | 1 |
| David H. Murdock Research Institute Acquires the Immune Tolerance Institute | 91 | 1 |
| Health Diagnostic Laboratory Acquires Harris Scientific | 91 | 1 |
| Myriad Genetics Acquires Rules-based Medicine | 92 | 1 |
| CIT Safety Acquires LAB Research | 92 | 1 |
| Quest Diagnostics Completes Acquisition of Celera | 92 | 1 |
| Licensing Agreement Deals | 93 | 1 |
| Licensing Agreement Deals by Geography | 94 | 1 |
| Major Licensing Agreements | 95 | 1 |
| AVEO Pharmaceuticals Enters Into Licensing Agreement with Centocor Ortho Biotech | 95 | 1 |
| Prometheus Laboratories Signs Licensing Agreement with Bayer Schering Pharma | 95 | 1 |
| Dana-Farber Enters Into Licensing Agreement with Sanofi | 96 | 1 |
| OSI Pharmaceuticals Enters Into Licensing Agreement with AVEO Pharmaceuticals | 96 | 1 |
| KineMed Extends Licensing Agreement with Bristol-Myers Squibb | 96 | 1 |
| Partnership Deals | 97 | 1 |
| Major Partnership Deals | 98 | 1 |
| BG Medicine Enters Into Research Collaboration with Boston Scientific | 98 | 1 |
| MdxHealth Enters Into Co-Development Agreement with Newcastle University, Cancer Research Technology and Pfizer | 98 | 1 |
| Takeda Pharmaceutical Enters Into Co-Development Agreement with Kyoto University | 99 | 1 |
| Merck Serono Enters Into Research Agreement with Philochem | 99 | 1 |
| Biomarkers in Drug Discovery Appendix | 100 | 4 |
| Market Definitions | 100 | 1 |
| Abbreviations | 100 | 1 |
| Research Methodology | 100 | 4 |
| Biomarkers in Drug Discovery- Overview | 101 | 1 |
| Biomarkers in Drug Discovery- Case Study | 101 | 1 |
| Biomarkers in Drug Discovery- Market Characterisation | 101 | 1 |
| Biomarkers in Drug Discovery- Trends Analysis | 101 | 1 |
| Biomarkers in Drug Discovery- Technology Adoptions | 101 | 1 |
| Biomarkers in Drug Discovery- Competitive Landscape | 101 | 1 |
| Biomarkers in Drug Discovery- Pipeline Analysis | 101 | 1 |
| Biomarkers in Drug Discovery- Strategic Consolidations | 102 | 1 |
| Coverage | 102 | 1 |
| Secondary Research | 102 | 1 |
| Primary Research | 102 | 1 |
| Expert Panel Validation | 103 | 1 |
| Contact Us | 103 | 1 |
| Disclaimer | 103 | 1 |
| Sources | 103 | 1 |